CDC-Funded Clinical Trial Testing Tenofovir for HIV Prevention to Begin Next Month in Bangkok
March 9, 2005
A CDC-funded, three-year clinical trial testing Gilead's antiretroviral drug Viread to determine its effectiveness in preventing HIV transmission is scheduled to begin next month in Bangkok, Thailand, the Bangkok Post reports (Wancharoen, Bangkok Post, 3/8). The drug, which is known generically as tenofovir, works by blocking HIV's reverse transcriptase enzyme to prevent replication. Tenofovir is FDA-approved for use as a treatment for HIV infection and has been shown to boost immune response and lower viral levels in the bloodstreams of patients who are resistant to other antiretrovirals (Kaiser Daily HIV/AIDS Report, 2/7). The trial, which has been approved by Thailand's Ministry of Public Health, will be conducted in the city by the Bangkok Metropolitan Administration at Taskin Hospital, BMA Deputy City Clerk Pitinan Natrujirote said. About 1,600 volunteers, including injection drug users and other people at high risk of contracting HIV, will be recruited to participate in the trial, Pitinan said (Bangkok Post, 3/8). CDC also has awarded $3.5 million in grants to fund trials of Viread in San Francisco and Atlanta.
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Boys' Perceived, Actual Condom Knowledge Possibly Related to Use During First Intercourse, Study Says
Taiwanese Health Dept. Considers Needle-Exchange Program to Reduce Spread of HIV Among Injection Drug Users
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.